In this respect, the results of the present study identify FD as a potential therapeutic target in cSCC and warrant further studies to evaluate the small-molecule FD inhibitor danicopan in targeted therapy of advanced cSCC and other cancers expressing high levels of FD. Here, ELP1 is linked to cancer.